<DOC>
	<DOCNO>NCT02483585</DOCNO>
	<brief_summary>A Phase 3 , Randomized , Double-blind , Placebo-controlled Study follow open-label treatment phase . To evaluate effect AMG 334 compare placebo change baseline monthly migraine day , subject episodic migraine</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety AMG 334 Compared Placebo Migraine Prevention</brief_title>
	<detailed_description>A Phase 3 , Randomized , Double-blind , Placebo-controlled Study follow open-label treatment phase . Adults history migraine without aura ≥ 12 month experience ≥ 4 &lt; 15 migraine day per month &lt; 15 headache day per month randomize 1:1 placebo AMG 334 . Double-blind AMG 334 placebo administer 12-week double-blind treatment phase open-label AMG 334 administer 28-week open-label treatment phase . Investigational product dos fix adjust individual subject study .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>History Migraines High migraine frequency Demonstrated compliance eDiary Older 50 year age migraine onset . History cluster headache hemiplegic migraine headache . Unable differentiate migraine headaches No therapeutic response &gt; 2 category prophylactic treatment migraine adequate therapeutic trial . Concomitant use 2 medication possible migraine prophylactic effect within 2 month prior start baseline phase baseline phase . If 1 prophylactic medication use , dose must stable within 2 month prior start baseline phase throughout study Used prohibit medication , device , procedure within 2 month prior start baseline phase baseline phase . Received botulinum toxin Anticipated require exclude medication , device , procedure study . Active chronic pain syndrome ( fibromyalgia chronic pelvic pain ) . History major psychiatric disorder . History seizure disorder significant neurological condition migraine . Human immunodeficiency virus ( HIV ) infection history . Myocardial infarction ( MI ) , stroke , transient ischemic attack ( TIA ) , unstable angina , coronary artery bypass surgery revascularization procedure within 12 month prior screen . The subject risk selfharm harm others . Previously randomize AMG 334 study . Unlikely able complete protocol require study visit procedure , and/or comply require study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
	<keyword>Episodic</keyword>
	<keyword>Prevention</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>